Teneligliptin

Generic Name
Teneligliptin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C22H30N6OS
CAS Number
760937-92-6
Unique Ingredient Identifier
28ZHI4CF9C
Background

Teneligliptin has been investigated for the treatment of Type 2 Diabetes Mellitus.

Indication

用于2型糖尿病患者。

Associated Conditions
Type 2 Diabetes Mellitus
Associated Therapies
-
Clinical Trials
Related News

Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Phase 1
Not yet recruiting
Conditions
Healthy Volunteers
Interventions
Drug: HD-P023
Drug: Teneligliptin
Drug: Empagliflozin
First Posted Date
2024-04-01
Last Posted Date
2024-04-02
Lead Sponsor
Handok Inc.
Target Recruit Count
40
Registration Number
NCT06339788

A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen

Phase 4
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Placebo
Drug: teneligliptin
First Posted Date
2020-06-24
Last Posted Date
2021-06-09
Lead Sponsor
Yonsei University
Target Recruit Count
100
Registration Number
NCT04446026
Locations
🇰🇷

Yonsei Severance Hospital, Seoul, Korea, Republic of

Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

First Posted Date
2020-06-16
Last Posted Date
2021-11-15
Lead Sponsor
Handok Inc.
Target Recruit Count
32
Registration Number
NCT04431141
Locations
🇰🇷

Clinical Pharmacology, Asan Medical Center, Seoul, Korea, Republic of

Tenelia Elderly CGMS Study(TEDDY)

Phase 4
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Teneligliptin
Drug: Placebo
First Posted Date
2018-04-25
Last Posted Date
2022-06-30
Lead Sponsor
Handok Inc.
Target Recruit Count
65
Registration Number
NCT03508323
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients

First Posted Date
2017-01-05
Last Posted Date
2019-02-22
Lead Sponsor
Handok Inc.
Target Recruit Count
168
Registration Number
NCT03011177
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

Tenelia Triple Combination Study

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Teneligliptin
First Posted Date
2015-10-05
Last Posted Date
2018-05-02
Lead Sponsor
Handok Inc.
Target Recruit Count
201
Registration Number
NCT02567994
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)

First Posted Date
2015-07-31
Last Posted Date
2015-10-06
Lead Sponsor
Handok Inc.
Target Recruit Count
40
Registration Number
NCT02512523
Locations
🇰🇷

HANDOK Inc., Seoul, Korea, Republic of

Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study

Phase 4
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Teneligliptin
First Posted Date
2015-05-20
Last Posted Date
2018-08-22
Lead Sponsor
National Cerebral and Cardiovascular Center, Japan
Target Recruit Count
936
Registration Number
NCT02449330
Locations
🇯🇵

National Cerebral and Cardiovascular Center, Suita, Japan

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

First Posted Date
2015-02-03
Last Posted Date
2018-11-01
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
138
Registration Number
NCT02354235
Locations
🇯🇵

Reserch site, Tohoku, Japan

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

First Posted Date
2015-02-03
Last Posted Date
2018-11-01
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
154
Registration Number
NCT02354222
Locations
🇯🇵

Reserch site, Tohoku, Japan

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy